Search Results - "Gambol, Teresa"

Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer by YU, Evan Y, KUO, Kevin F, GULATI, Roman, SHU CHEN, GAMBOL, Teresa E, HALL, Suzanne P, JIANG, Peter Y, PITZEL, Peggy, HIGANO, Celestia S

“…To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic,…”
Get full text

Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer by Kuo, Kevin F, Hunter-Merrill, Rachel, Gulati, Roman, Hall, Suzanne P, Gambol, Teresa E, Higano, Celestia S, Yu, Evan Y

“…Micro-Abstract The kinetics and relationships between testosterone (T) and prostate-specific antigen (PSA) during the first off-treatment interval in men with…”
Get full text

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy by Hirata, Yoshito, Morino, Kai, Akakura, Koichiro, Higano, Celestia S, Bruchovsky, Nicholas, Gambol, Teresa, Hall, Susan, Tanaka, Gouhei, Aihara, Kazuyuki

“…When a physician decides on a treatment and its schedule for a specific patient, information gained from prior patients and experience in the past is taken…”
Get full text

A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD) by Yu, Evan Y., Kuo, Kevin F, Hunter-Merrill, Rachel, Gulati, Roman, Cheng, Heather H., Flamiatos, Jason Frederick, Gambol, Teresa E, Hall, Suzanne P, Higano, Celestia S.

“…Abstract only 209 Background: Exisulind is an apoptotic drug shown in vitro to inhibit expression and function of the androgen receptor. At lower doses as a…”
Get full text

Time to testosterone (T) and PSA rises during first “off treatment” interval (1OFF-2ON) of intermittent androgen deprivation (IAD) as prognostic for time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR) by Yu, Evan Y., Kuo, Kevin F, Hunter-Merrill, Rachel, Gulati, Roman, Hall, Suzanne P, Gambol, Teresa E, Etzioni, Ruth D, Higano, Celestia S.

“…Abstract only 4557 Background: A recent phase III trial of intermittent vs. continuous AD supports IAD as standard of care for men treated with AD for BR. To…”
Get full text

Relationship of time to testosterone (T) and PSA rises during the first “off treatment” interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR) by Yu, Evan Y., Kuo, Kevin F, Hunter-Merrill, Rachel, Gulati, Roman, Hall, Suzanne P, Gambol, Teresa E, Etzioni, Ruth D, Higano, Celestia S.

“…Abstract only 99 Background: A recent phase III trial of intermittent vs. continuous AD supports IAD as standard of care for men treated with AD for BR. To…”
Get full text

Relationships between times to testosterone and prostate-specific antigen rises during the first “off treatment” interval of intermittent androgen deprivation are prognostic for castration-resistance in men with non-metastatic prostate cancer by Kuo, Kevin F., Hunter-Merrill, Rachel, Gulati, Roman, Hall, Suzanne P., Gambol, Teresa E., Higano, Celestia S., Yu, Evan Y.

Get full text